Partial metabolic interventions (e.g., mTOR inhibition alone) suppress SASP secretion but leave growth arrest intact because they fail to restore epigenetic architecture at senescence-associated heterochromatin foci (SAHF). Complete NAD+ restoration activates SIRT1, which deacetylates H3K9 and recruits SUV39H1/HP1 to re-establish heterochromatin, allowing silencing of p16INK4a and re-expression of E2F-target proliferation genes. This predicts that single-agent senolytics or mTOR inhibitors halt neurodegeneration-associated senescence progression, but combinatorial NAD+ boosting with SIRT1 activation achieves true reversal of established senescent phenotypes in neurons and glia.
Curated pathway from expert analysis
flowchart TD
A["NAD+ Restoration<br/>SIRT1 Activation"]
B["H3K9me3<br/>Epigenetic Reset"]
C["Senescence Reversal<br/>Growth Arrest Relief"]
D["Incomplete Metabolic<br/>Reprogramming Caveat"]
E["SASP Suppression<br/>without Growth Arrest"]
F["SIRT1 as<br/>NAD+-Sirtuin Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for SIRT1 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SIRT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 5xFAD mice (n=20/genotype) receive dietary nicotinamide riboside supplementation (1200mg/kg chow) combined with SRT2104 (30mg/kg/day ip) from 9-12 months of age THEN spatial memory reversal (Barnes | NR+SRT2104 treated 5xFAD mice will exhibit both reversal of established cognitive deficits and reduction in p16INK4a+ senescent neurons, while rapamycin-treated | — no observation — | pending | 0.55 |
| IF human iPSC-derived neurons carrying familial AD mutations are treated with nicotinamide riboside (NR, 1mM) + SIRT1 activator (SRT2104, 1μM) for 14 days THEN a composite senescence reversal score (p | Combinatorial NAD+ boosting with SIRT1 activation will achieve ≥60% reduction in p16INK4a mRNA, ≥2-fold increase in H3K9me3 ChIP signal at CDKN2A promoter, and | — no observation — | pending | 0.62 |